Chief Executive Officer, President and Director · IGM Biosciences, Inc. (IGMS)

Fred Schwarzer

A named executive officer of IGM Biosciences in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2023

$3,207,328

FY2022: $5,316,460

1st of 3 named executive officers at IGM Biosciences by FY2023 total.

3 named officers on file for IGM Biosciences, FY2023

See an example →

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Fred Schwarzer’s full pay file as a PDF — free

More than this page: up to 10 years of Fred’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Fred Schwarzer and every company like it: Velarion Intel, free for 3 days, no card →

Fred Schwarzer compensation by year

IGM Biosciences Summary Compensation Table · all 2 fiscal years held
In US dollars, as IGM Biosciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$621,920$646,797
Bonus$0$0
Stock awards$6,782$868,050
Option awards$4,332,020$1,336,743
Non-equity incentive$355,738$355,738
Pension and deferred compensation$0$0
All other$0$0
Total$5,316,460$3,207,328

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IGM Biosciences, Inc. DEF 14A filed April 26, 2024, accession 0000950170-24-049091, and prior-year filings. Open the filing on EDGAR.

How this page was built: the IGM Biosciences, Inc. filed document, accession 0000950170-24-049091. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$5.3M
$3.2M
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awards

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU67,500$560,925—
Option109,688—$12.86
Option196,875—$17.11
Option6,250—$40.27
Option36,459—$91.50

Per the Outstanding Equity Awards at Fiscal Year-End table in IGM Biosciences, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

IGM Biosciences’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Fred Schwarzer · this pageChief Executive Officer, President and Director$3,207,328
Bruce KeytChief Scientific Officer$1,571,204
Chris TakimotoChief Medical Officer$1,562,812

Board service

IGM Biosciences board · FY2023

How this board is paid

Company policy: IGM Biosciences pays directors a $40,000 cash retainer. As stated in IGM Biosciences's FY2023 proxy.

The full IGM Biosciences compensation record

free company brief

This page is one person within IGM Biosciences's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the IGM Biosciences proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IGM Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Fred Schwarzer's compensation dossier